MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”,
the “Company”), a clinical-stage biopharmaceutical company
developing targeted immunotherapies for cancer, today announced
that two of the Company’s independent directors, Ramiro Guerrero,
JD, LL.M. and Stan V. Smith, Ph.D., purchased MAIA’s common stock
and warrants in each of the Company’s recent private placement
closings which occurred on November 1, 2024, and December 13, 2024.
Total gross proceeds to MAIA from the closings were $3.4
million.
Mr. Guerrero purchased a total of 141,952 shares and 141,952
warrants for an aggregate purchase price of approximately $300,000.
Dr. Smith purchased a total of 125,000 shares and 125,000 warrants
for an aggregate purchase price of approximately $273,000.
“As always, we much appreciate the continuing support by our
directors and their commitment to our scientific innovation and
successful clinical progress,” said Vlad Vitoc, M.D., CEO of
MAIA.
“I believe MAIA is well positioned to create a great deal of
value for its shareholders over time,” said Mr. Guerrero, director
and long-term investor. “My increasing investment reflects my
confidence in MAIA’s clinical strategy and THIO’s transformative
potential for multiple hard-to-treat cancer indications.”
Mr. Guerrero is the founder and CEO of IMPERIO, Inc., a
Chicago-based real estate investment and brokerage organization. In
addition to his 20+ years in real estate, Mr. Guerrero is a venture
capitalist aiding entrepreneurs and small businesses in business
startups. Mr. Guerrero made individual purchases in MAIA’s earlier
private placement transactions.
Dr. Smith is one of MAIA’s original investors and has
participated in nearly every private placement financing round
since the Company’s inception. In recent remarks, he shared his
belief in the extraordinary market potential for MAIA’s THIO
franchise.
Additional details on the private placement can be found in the
Company’s Current Report on Form 8-K filed with the Securities and
Exchange Commission on December 10, 2024, at www.sec.gov.
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class
investigational telomere-targeting agent currently in clinical
development to evaluate its activity in Non-Small Cell Lung Cancer
(NSCLC). Telomeres, along with the enzyme telomerase, play a
fundamental role in the survival of cancer cells and their
resistance to current therapies. The modified nucleotide
6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent
telomeric DNA modification, DNA damage responses, and selective
cancer cell death. THIO-damaged telomeric fragments accumulate in
cytosolic micronuclei and activates both innate (cGAS/STING) and
adaptive (T-cell) immune responses. The sequential treatment with
THIO followed by PD-(L)1 inhibitors resulted in profound and
persistent tumor regression in advanced, in vivo cancer models by
induction of cancer type–specific immune memory. THIO is presently
developed as a second or later line of treatment for NSCLC for
patients that have progressed beyond the standard-of-care regimen
of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, and (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and
expectations by our management that, although we believe to be
reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is
expressed in good faith and believed to be reasonable at the time
such forward-looking statement is made. However, these statements
are not guarantees of future events and are subject to risks and
uncertainties and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241219472539/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
